Exploring the Expression of Survivin on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma

Authors

  • Primariadewi Rustamadji Department of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Elvan Wiyarta Department of Medical Science, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia https://orcid.org/0000-0002-5676-7804
  • Ineke Anggreani Department of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.9940

Keywords:

Survivin, Taxane, Chemotherapy, Breast Cancer, Invasive

Abstract

Background:   Biomarkers are required to monitor the response to neoadjuvant chemotherapy (NC) in patients with invasive breast cancer (IBC). The purpose of this study is to determine the function of Survivin in the administration of NC, both taxane- and non-taxane-based, to patients with IBC.

Methods: Thirty-one samples were categorized according to the NC's administrative status (before or after) and the type of NC used (taxane- or non-taxane-based). Age, tumor grade, receptor status (ER, PR, HER2, Ki-67), and survivin expression were evaluated. Survivin expressions were evaluated by IHC staining and categorized according median H-score cut-offs, while other data were collected from archives. Data was gathered and analyzed using generalized linear model. 

Results:  Survivin expression decreased following NC administration, although not significantly (p=0.285). The taxane group had lower survivin expression. Statistically, this was not significant (p=0.329). The non-taxane group had the same outcome (p=0.792). The decline in survivin expression was greater in the taxane group than in the non-taxane group, although it was not statistically significant (p=0.369).

Conclusion: Although the changes in survivin expression were not statistically significant, when clinical and laboratory data are analyzed, survivin expression has the potential to be a predictive biomarker of NC response as well as clinical outcome in IBC.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence in 2020: International Agency for Research on Cancer. Geneva, Switzerland: WHO; 2020.

Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: An overview. J Adv Pharm Technol Res. 2010;1(2):109-26. PMid:22247839

Rustamadji P, Wiyarta E, Bethania KA, Kusmardi K. Potential of AKT2 expression as a predictor of lymph-node metastasis in invasive breast carcinoma of no special type. J Pathol Transl Med. 2021;55(4):271-8. https://doi.org/10.4132/jptm.2021.04.26 PMid:34111909 DOI: https://doi.org/10.4132/jptm.2021.04.26

Rustamadji P, Wiyarta E, Bethania KA. CD44 Variant Exon 6 Isoform Expression as a Potential Predictor of Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type. Int J Breast Cancer. 2021;2021:1586367. https://doi.org/10.1155/2021/1586367 PMid:34925920 DOI: https://doi.org/10.1155/2021/1586367

Lee A, Lim W, Moon BI, Paik NS, Koh SH, Song JY. Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy. J Breast Cancer. 2011;14(4):283-8. https://doi.org/10.4048/jbc.2011.14.4.283 PMid:22323914 DOI: https://doi.org/10.4048/jbc.2011.14.4.283

Zhang Z, Zhang X, Chen S, Jiang J, Qi R, Zhang X, et al. Taxane-based chemotherapy and risk of breast cancer-related lymphedema: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(30):e16563. https://doi.org/10.1097/MD.0000000000016563 PMid:31348280 DOI: https://doi.org/10.1097/MD.0000000000016563

Biliran H Jr., Wang Y, Banerjee S, Xu H, Heng H, Thakur A, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res. 2005;11(16):6075-86. https://doi.org/10.1158/1078-0432.CCR-04-2419 PMid:16115953 DOI: https://doi.org/10.1158/1078-0432.CCR-04-2419

Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: A unique target for tumor therapy. Cancer Cell Int. 2016;16:49. https://doi.org/10.1186/s12935-016-0326-1 PMid:27340370 DOI: https://doi.org/10.1186/s12935-016-0326-1

Pacifico F, Leonardi A. NF-kappaB in solid tumors. Biochem Pharmacol. 2006;72(9):1142-52. https://doi.org/10.1016/j.bcp.2006.07.032 PMid:16956585 DOI: https://doi.org/10.1016/j.bcp.2006.07.032

Chen X, Duan N, Zhang C, Zhang W. Survivin and tumorigenesis: Molecular mechanisms and therapeutic strategies. J Cancer. 2016;7(3):314-23. https://doi.org/10.7150/jca.13332 PMid:26918045 DOI: https://doi.org/10.7150/jca.13332

Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8:34. https://doi.org/10.1186/s40364-020-00209-0 PMid:32864131 DOI: https://doi.org/10.1186/s40364-020-00209-0

Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964;2(5402):177. https://doi.org/10.1136/bmj.2.5402.177 PMid:14150898 DOI: https://doi.org/10.1136/bmj.2.5402.177

Kusmardi K, Wiyarta E, Estuningtyas A, Sahar N, Midoen YH, Tedjo A. Potential of phaleria macrocarpa leaves ethanol extract to upregulate the expression of caspase-3 in mouse distal colon after dextran sodium sulphate induction. Pharmacogn J. 2021;13:23-9. DOI: https://doi.org/10.5530/pj.2021.13.4

Kusmardi K, Wiyarta E, Estuningtyas A, Sahar N, Midoen YH, Tedjo A, et al. Potential inhibition by phaleria macrocarpa leaves ethanol extract on Ki-67 expression in distal colon mouse. Pharmacogn J. 2021;13:443-9. DOI: https://doi.org/10.5530/pj.2021.13.56

Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, et al. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. Ann Oncol. 2014;25(10):1973-9. https://doi.org/10.1093/annonc/mdu247 PMid:25009009 DOI: https://doi.org/10.1093/annonc/mdu247

Kusmardi K, Wiyarta E, Rusdi NK, Maulana AM, Estuningtyas A, Sunaryo H. The potential of lunasin extract for the prevention of breast cancer progression by upregulating E-Cadherin and inhibiting ICAM-1. F1000Res. 2021;10:902. https://doi.org/10.12688/f1000research.55385.1 PMid:34691393 DOI: https://doi.org/10.12688/f1000research.55385.1

O’Brien J, Hayder H, Peng C. Automated quantification and analysis of cell counting procedures using imagej plugins. J Vis Exp. 2016;17(117):e54719. https://doi.org/10.3791/54719 PMid:27911396 DOI: https://doi.org/10.3791/54719

Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem. 2010;58(2):95-107. https://doi.org/10.1369/jhc.2009.953554 PMid:19687472 DOI: https://doi.org/10.1369/jhc.2009.953554

Lv YG, Yu F, Yao Q, Chen JH, Wang L. The role of survivin in diagnosis, prognosis and treatment of breast cancer. J Thorac Dis. 2010;2(2):100-10. PMid:22263027

Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14(16):5000-5. https://doi.org/10.1158/1078-0432.CCR-08-0746 PMid:18698017 DOI: https://doi.org/10.1158/1078-0432.CCR-08-0746

Liu F, Xie ZH, Cai GP, Jiang YY. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull. 2007;30(12):2279-83. https://doi.org/10.1248/bpb.30.2279 PMid:18057712 DOI: https://doi.org/10.1248/bpb.30.2279

Notarbartolo M, Cervello M, Dusonchet L, Cusimano A, D’Alessandro N. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett. 2002;180(1):91-101. https://doi.org/10.1016/s0304-3835(01)00834-5 PMid:11911975 DOI: https://doi.org/10.1016/S0304-3835(01)00834-5

Appleyard MV, O’Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, et al. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer. 2009;124(2):465-72. https://doi.org/10.1002/ijc.23938 PMid:19003963 DOI: https://doi.org/10.1002/ijc.23938

Wu YK, Huang CY, Yang MC, Lan CC, Lee CH, Chan EC, et al. Nuclear survivin expression: A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer. Med Oncol. 2014;31(8):79. https://doi.org/10.1007/s12032-014-0079-4 PMid:24961465 DOI: https://doi.org/10.1007/s12032-014-0079-4

Han TL, Sha H, Ji J, Li YT, Wu DS, Lin H, et al. Depletion of Survivin suppresses docetaxel-induced apoptosis in HeLa cells by facilitating mitotic slippage. Sci Rep. 2021;11(1):2283. https://doi.org/10.1038/s41598-021-81563-3 PMid:33504817 DOI: https://doi.org/10.1038/s41598-021-81563-3

Goričar K, Kovač V, Franko A, Dodič-Fikfak M, Dolžan V. Serum survivin levels and outcome of chemotherapy in patients with malignant mesothelioma. Dis Markers. 2015;2015:316739. https://doi.org/10.1155/2015/316739 PMid:26451067 DOI: https://doi.org/10.1155/2015/316739

Thangavel C, Boopathi E, Liu Y, McNair C, Haber A, Perepelyuk M, et al. Therapeutic challenge with a CDK 4/6 inhibitor induces an RB-dependent SMAC-mediated apoptotic response in non-small cell lung cancer. Clin Cancer Res. 2018;24(6):1402-14. https://doi.org/10.1158/1078-0432.CCR-17-2074 PMid:29311118 DOI: https://doi.org/10.1158/1078-0432.CCR-17-2074

Roberts PJ, Kumarasamy V, Witkiewicz AK, Knudsen ES. Chemotherapy and CDK4/6 Inhibitors: Unexpected bedfellows. Mol Cancer Ther. 2020;19(8):1575-88. https://doi.org/10.1158/1535-7163.MCT-18-1161 PMid:32546660 DOI: https://doi.org/10.1158/1535-7163.MCT-18-1161

Downloads

Published

2022-06-05

How to Cite

1.
Rustamadji P, Wiyarta E, Anggreani I. Exploring the Expression of Survivin on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma. Open Access Maced J Med Sci [Internet]. 2022 Jun. 5 [cited 2024 Mar. 29];10(B):1440-5. Available from: https://oamjms.eu/index.php/mjms/article/view/9940

Similar Articles

You may also start an advanced similarity search for this article.